Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Ingelheim, MorphoSys Expand Antibody-development Collaboration

NEW YORK, March 18 (GenomeWeb News) - Boehringer Ingelheim has obtained from MorphoSys the option to exclusively license several therapeutic antibodies being co-developed by the firms under a previous agreement with the two companies, the company said today.

Under the agreement, which expands a previous therapeutic antibody collaboration between the two companies, Behringer will also obtain access to MorphoSys's HuCal Gold library, taking installation first at its site in Vienna.

Boehringer will pay MorphoSys an undisclosed technology access fee, annual licenses fees, and optional R&D funding over the 5-year term of the collaboration. It will also pay milestone fees and royalties for any therapeutic antibodies emerging from the collaboration.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.